Description: Plazomicin is a next-generation aminoglycoside that has been designed as an antibiotic to avoid resistance through aminoglycoside-modifying enzymes. Plazomicin demonstrates high activity against the Enterobacteriaceae including extended spectrum beta lactamase and most carbapenemase producers, and can be useful in treating complicated urinary tract infections (cUTIs) and acute pyelonephritis. It is undergoing Phase III clinical studies.